PT-2385, hypoxia inducible factor (ab235501)

Overview

  • Product name

    PT-2385, hypoxia inducible factor
  • Description

    Potent and selective inhibitor of hypoxia inducible factor
  • Biological description

    Potent and selective inhibitor of hypoxia inducible factor (HIF-2α) with potential antineoplastic activity. PT-2385 selectively disrupts the heterodimerization of HIF-2α with HIF-1β. Very effective in blocking cancer cell growth, proliferation, and tumor angiogenesis  in clear cell renal cell carcinoma (ccRCC).

  • Purity

    > 98%
  • CAS Number

    1672665-49-4
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile

  • Molecular weight

    383.34
  • Molecular formula

    C17H12F3NO4S
  • PubChem identifier

    91754484
  • Storage instructions

    Shipped at Room Temperature. Store at -20°C. It is important to note that this is air sensitive and impurities can occur as a result of air oxidation. Store In the Dark. Store under desiccating conditions.
  • Solubility overview

    DMSO

  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CS(=O)(=O)C1=C2C(C(CC2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)(F)F)O
  • Source

    Synthetic

References

This product has been referenced in:

  • Toledo RA New HIF2a inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas. Endocr Relat Cancer 24:C9-C19 (2017). Read more (PubMed: 28667082) »
  • Xu J  et al. Increasing AR by HIF-2a inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis 8:e3095 (2017). Read more (PubMed: 29022906) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab235501.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up